PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine

Autor: Martina Mandarano, Matthew Blackburn, Maysa M. Abu-Khalaf, Rosa I. Gallagher, Guido Gambara, Vienna Ludovini, Giuseppina Improta, Guido Bellezza, Julia Wulfkuhle, Angela Zupa, Neil J Shah, Giuseppe Giaccone, Johann S. de Bono, Lance A. Liotta, K. Alex Hodge, Antonella Ravaggi, Franco Odicino, Ruth Riisnaes, Maria Isabella Sereni, Chamodya Ruhunusiri, Mariaelena Pierobon, Niven Mehra, Elisa Baldelli, Emanuel F. Petricoin, Perry Demsko, Bryant Dunetz, Lucio Crinò, Angelo Sidoni

Publikováno v: Journal for Immunotherapy of Cancer, 9
Journal for Immunotherapy of Cancer, 9, 10
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)

BackgroundAnti-programmed cell death protein 1 and programmed cell death ligand 1 (PD-L1) agents are broadly used in first-line and second-line treatment across different tumor types. While immunohistochemistry-based assays are routinely used to asse

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24903e020ae56015c56cfa9ba842008c
https://doi.org/10.1136/jitc-2020-002179